News | January 29, 2022
DCGI approves Bharat Biotech’s Phase 3 trials for intranasal vaccine
Intranasal vaccines are easier to administer in mass immunisation campaigns and help reduce or stop transmission
Intranasal vaccines are easier to administer in mass immunisation campaigns and help reduce or stop transmission
The aim is to strengthen industry-academia cooperation
The award was given as a result of NASSCOM's meticulous screening process, in which over 700 start-ups were shortlisted as the most promising companies of the year
The vaccines are currently only authorised for emergency use in the country
This will evaluate the immunogenicity, safety, and reactogenicity of a single booster dose in adults aged 18 years and older
_256_384.jpg)
Closing the Loop on single-use plastics
The collaboration with Sanofi signifies a considerable investment in the UK’s Life Sciences sector and, along with other future strategic partners, has the potential to increase the pipeline of potential treatment options for a wide range of common and other life-threatening diseases
The country is sixth among the most affected countries by active cases
Previously, the use of the drug was limited to patients requiring hospitalization
Omicron patients below 60 with no comorbidities can start treatment with paracetamol
Subscribe To Our Newsletter & Stay Updated
